Clinical trials: Dengue Virus Infection
Hyponatremia, Dengue
Prevalence of Hyponatremia in Dengue Infected Patients: Relationship With Systemic Inflammation.
Prospective cohort study in patients with newly diagnosed dengue infection at Hospital Posadas in Argentina, between January 1, 2016, and November 1, 2023. Diagnosis was confirmed by IgM serology or PCR.
- Conditions
- Hyponatremia, Dengue, Inflammation
- Trial name
- HINDIP (NCT06109532)
- Testing
- hyponatremia
- Where
- 2 sites in Argentina
- Volunteers
- 530 people
- Sponsor
- Hospital Nacional Profesor Alejandro Posadas
Dengue
Clinical Trial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan
Phase II, randomized, double-blind, placebo-controlled study of the safety and immunogenicity of the recombinant live attenuated tetravalent dengue virus vaccine admixture TV005 in the elderly in Taiwan
- Trial name
- NCT04133987
- Testing
- Tetravalent live attenuated dengue vaccine admixture TV005
- Where
- Taiwan
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Dengue Virus Infection
Observational Study to Evaluate the Safety of CYD Tetravalent Dengue Vaccine (CYD-TDV) in Pregnant Women and Their Offsprings Inadvertently Exposed During Pregnancy
Primary Objective: To evaluate the safety of CYD-TDV in pregnant women and their offsprings inadvertently exposed during pregnancy or up to 30 days preceding their last menstrual period (LMP) with regards to maternal, pregnancy…
- Trial name
- NCT04023708
- Testing
- CYD-TDV Dengue Vaccine
- Where
- Brazil
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever, Dengue Hemorrhagic Fever
A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines
The purpose of this study is to investigate the potential for co-administration of the first dose of CYD Dengue vaccine with childhood vaccination.
- Trial name
- NCT01064141
- Testing
- Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus, OKAVAX®:Attenuated live varicella-zoster virus and AVAXIM® 80U: Hepatitis A virus Vaccines, Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and Childhood vaccines
- Where
- Philippines
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dengue Fever, Dengue Hemorrhagic Fever
Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US
This study used 3 different formulations of tetravalent CYD dengue vaccine. The primary objective of the study was to evaluate the neutralizing antibody response after 2 doses of two different formulations of tetravalent dengue…
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Dengue Virus
- Trial name
- NCT00617344
- Testing
- Tetravalent CYD Dengue Vaccine , 5555 formulation, Tetravalent CYD Dengue Vaccine , 5553 formulation, Tetravalent CYD Dengue Vaccine, 4444 formulation
- Where
- 5 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Sanofi
Fever, Dengue
Cohort of Patients Infected by an Arbovirus
There are hundred of arbovirus which have been shown to cause disease in humans. Their most common clinical symptoms are algo-eruptive (dengue, chikungunya, zika), hemorrhagic fever (dengue, yellow fever, Crimean-Congo…
- Conditions
- Fever, Dengue, Chikungunya, Zika Virus
- Trial name
- CARBO (NCT01099852)
- Testing
- biological sample collection, Quality of life Questionnaire EuroQol®, Health Assessment Questionnaire - MDHAQ and RAPID3
- Where
- 8 sites in France, French Guiana and 3 more
- Volunteers
- 1,377 people
- Sponsor
- University Hospital Center of Martinique
Dengue
A Study of JNJ-64281802 for the Prevention of Dengue Infection
The purpose of this study is to evaluate the prophylactic effect of JNJ-64281802 with respect to the prevention of laboratory-confirmed dengue virus (DENV) infection up to the last day of dosing among participants who have no…
- Trial name
- NCT05201794
- Testing
- JNJ-64281802
- Where
- 38 sites in Brazil, Colombia and 7 more
- Volunteers
- 1,595 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Dengue Virus, Dengue Fever
Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults
This is part of an ongoing effort to develop a satisfactory dengue vaccine: Primary objective: To describe the safety after each vaccination with bivalent and tetravalent formulations of dengue vaccine candidates.
- Conditions
- Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever, Dengue Diseases
- Trial name
- NCT00740155
- Testing
- Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero), Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero), Tetravalent CYD-1,2,3,4 Dengue (Vero)
- Where
- 2 sites in Mexico
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue, Dengue Hemorrhagic Fever
Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America
The purpose of this study is to generate immunogenicity and safety data in preparation for efficacy studies in Latin America. Primary Objectives: To describe the immune response to dengue viruses before and after each vaccination…
- Trial name
- NCT01187433
- Testing
- Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus, NaCl 0.9%, Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed
- Where
- Brazil
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever
Factors Associated With Poor Dengue Outcomes in Malaysia
This study aims to analyse the results of national data collected by the e-Dengue Information System in order to determine the factors associated with disease outcomes in all patients registered from January 2013 to December 2014.
- Trial name
- NCT02510690
- Where
- Malaysia
- Volunteers
- 20,000 people
- Sponsor
- Clinical Research Centre, Malaysia
Dengue
Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001)
This study will determine whether at least one formulation of an experimental dengue vaccine (V180) is safe and causes an immune response.
- Trial name
- NCT01477580
- Testing
- Low-dose V180 with low-dose ISCOMATRIX™ adjuvant, Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant, Medium-dose V180 (non-adjuvanted)
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Malaria, Dengue
Validation of a CDSA Strategy to Reduce Antibiotic Prescription in Senegal
This trial aims to validate a novel clinical care strategy based on a electronic clinical decision support algorithm (CDSA) combined with point of care rapid diagnostic tests by evaluating its impact on antibiotic prescription…
- Conditions
- Malaria, Dengue, Influenza -Like Illness, Diarrhea
- Trial name
- NCT05050825
- Testing
- Patient clinical management based on the CDSA strategy
- Where
- 4 sites in Senegal
- Volunteers
- 470 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Dengue
Homologous Re-infection With Dengue 1 or Dengue 3
Previous studies with one dengue infection in a controlled environment at Upstate generated data that has been important in understanding the clinical signs and symptoms and how a person's body reacts to dengue infection over…
- Trial name
- NCT05967455
- Testing
- Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC), Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- State University of New York - Upstate Medical University
West Nile Virus
Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age
West Nile virus (WNV) is considered an emerging virus in the United States, and infection can lead to severe illness in older adults.
- Trial name
- NCT02186626
- Testing
- WN/DEN4Δ30 Vaccine
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Volunteers
A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers
AV-1 is a human monoclonal antibody (mAb) being investigated as a potential therapy for dengue, a mosquito-borne viral disease with extensive global public health impact.
- Trial name
- NCT04273217
- Testing
- AV-1
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- AbViro LLC
Dengue
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults
Dengue fever, caused by dengue viruses, is a major health problem in the tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in…
- Trial name
- NCT00375726
- Testing
- rDEN3/4delta30(ME)
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue
Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults
Dengue viruses infect millions of people throughout the tropics and subtropics each year. The development of a dengue vaccine is an important health priority.
- Trial name
- NCT02392325
- Testing
- rDEN1Δ30, rDEN2Δ30-7169
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue, Dengue Fever
Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus Infection
This 3-year prospective observational study aims to identify clinical and laboratory risk factors associated with hospitalization in patients with confirmed dengue virus infection.
- Conditions
- Dengue, Dengue Fever, Dengue Fever With Warning Signs
- Trial name
- DENGUE-FACT (NCT07007585)
- Where
- Mexico
- Volunteers
- 100 people
- Sponsor
- Jose Ivan Rodriguez de Molina Serrano
Dengue Virus
Safety and Immune Response to an Investigational Dengue Type 2 Vaccine
Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world.
- Trial name
- NCT01073306
- Testing
- Investigational Vaccine for Dengue Virus Subtype 2
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue, Dengue Fever
Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children
This is a descriptive prospective community-based seroprevalence study. Primary objective: To determine the prevalence of specific antibodies (immunoglobulin G [IgG]) against dengue in healthy 5 to 10 year-old children in India.
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01477671
- Where
- 4 sites in India
- Volunteers
- 667 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company